Advertisement for orthosearch.org.uk
Results 1 - 1 of 1
Results per page:
Orthopaedic Proceedings
Vol. 94-B, Issue SUPP_XXXIV | Pages 4 - 4
1 Jul 2012
Subramanian P Kantharuban S Shilston S Pearce O
Full Access

We present the 12 month data on the relatively novel drug Dabigatran Etexilate (Pradaxa), a new oral anticoagulant which was introduced to combat the risk of post operative venous-thromboembolic disease (VTED) in orthopaedic surgery. This drug was introduced at our hospital in March 2010 and we present our modified protocol of: using 5000u subcutaneous Dalteparin whilst in hospital and giving Dabigatran only on discharge, and at a lower dose (150mg compared to 220mg).

We carried out a retrospective analysis of the notes and imaging of every patient who underwent elective hip and knee arthroplasty over 12 months since the drug was introduced. We evaluated the rate of VTED complications and the rate of transfusion and bleeding post operatively.

The case series of 370 patients showed a 1% risk of deep vein thrombosis with no pulmonary emboli and 1 death due to an unrelated cause. There was a transfusion rate of 11% with 0.5% patients taken back to theatre for evacuation of haematomas. There were no reported adverse effects of Dabigatran.

We argue that our modified protocol for this novel drug should be followed as it is both safe and effective for postoperative anticoagulation.